D-0278-2023 Class II Terminated
FDA drug recall D-0278-2023 was initiated by Sentara Infusion Services on Dec 27, 2022 and is designated Class II. Reason for recall: Lack of sterility assurance The recall status is terminated (terminated Feb 20, 2026). Affected quantity: 111 bags total 21 syringes total.
Recall Details
- Product Type
- Drugs
- Report Date
- Feb 22, 2023
- Initiation Date
- Dec 27, 2022
- Termination Date
- Feb 20, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 111 bags total 21 syringes total
Product Description
CEFAZOLIN (a) 12GM IN NS 600ML, (b) 2GM IN NS 100ML, (c) 2GM/20ML SW SYRINGE, (d) 3GM IN NS 150ML, antibiotic, used with a curlin, home or no pump assigned. Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
Reason for Recall
Lack of sterility assurance
Distribution Pattern
Dispensed to Patients Nationwide.
Code Information
Beyond Use By: December 25-31, 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0278-2023
- openFDA file date
- Oct 21, 2026
- Loaded by RegDataLab
- Oct 23, 2026